Eyeworld

EW NEWS & OPINION October 2016 35 Anew Optics (Newton Centre, Massa- chusetts), and Advanced Vision Science (Goleta, California). Drs. Assia, Mal- yugin, and Yamane have no financial interests related to their comments. (FAB). The patient would wash the finger with an alcohol swab, prick the finger with a diabetic lancet, allow a drop of blood to form, and apply the blood to the lower fornix of the affected eye. In the study, 15 patients were recruited—12 with dry eyes (21 eyes) and three with persistent epithelial defects. The results found that FAB can be effective for dry eyes, as well as for persistent epithelial defects. There were no adverse events noted so far, and it's a low cost method. Kuldev Singh, MD, professor of ophthalmology, Stanford Universi- ty, Palo Alto, California, called the idea a "very clever," less expensive alternative to autologous serum for this purpose. "It may not be suitable for every patient with dry eye, but it is worth exploring further in a clinical study," he said. One of the papers discussed among the panel was "Chemical basis for alteration of an intraocular lens using a femtosecond laser," which was presented by Josef Bille, PhD, Frankfurt, Germany, during a free paper session about cataract surgery instrumentation and surgical devices. This paper described in vivo modification of an IOL using a fem- tosecond laser. Dr. Singh said that this technol- ogy, if found to be safe, could "be a tremendous contribution to multifo- cal [IOLs]," particularly if physicians could take a patient who is unhappy with a multifocal implant and con- vert the lens to a monofocal, thereby eliminating the need for subsequent IOL exchange. David Spalton, MD, London, however, noted that one thing that hasn't been discussed in papers about this technology is what happens to transparency of the lens with such modifications. The session also included high- lights of some of the symposia topics including subluxated cataracts, uses for the femtosecond laser and other laser states, intraoperative aberrome- try, and high definition OCT. EW Editors' note: Dr. Bille has financial interests with Perfect Lens (Irvine, California). Dr. Singh has financial in- terests with Alcon (Fort Worth, Texas), Abbott Medical Optics (Abbott Park, Illinois), Santen (Osaka, Japan), and Carl Zeiss Meditec (Jena, Germany). Dr. Spalton has financial interests with Contact information Assia: assia@netvision.net.il Bille Josef.bille@urz.uni-heidelberg.de Malyugin: boris.malyugin@gmail.com (800) 367-8327 DuPont, WA 98327 info@lacrimedics.com • www.lacrimedics.com ©2016 Lacrimedics, Inc. 1 ASCRS Clinical Survey 2015. Global Trends in Ophthalmology and the American Society of Cataract and Refractive Surgery. 2 Offer valid through April 30, 2016. Don't let 41% of your patients with OSD go untreated, especially when they need something more than artifi cial tears. Lacrimedics' VisiPlug® is FDA approved for the treatment of the Dry Eye components of varying Ocular Surface Diseases (OSD) and after surgery to prevent complications due to Dry Eye Disease. VisiPlug® - Provides approximately 180 days of occlusion. Call 1-800-367-8327 and receive 15% OFF 2 your order! (Mention promo code OSD0416.) Don't let 41% of your patients 41% of refractive or cataract surgery patients have ocular surface dysfunction levels requiring some treatment beyond artifi cial tears! 1 0.4mm 0.5mm Singh: Kuldev.Singh@stanford.edu Spalton: profspalton@gmail.com Yamane: shinyama@yokohama-cu.ac.jp

• Cover